Zhongzhi Pharmaceutical (HKG:3737) expects a 45% year-over-year decline in net profit in 2024, a Friday bourse filing said.
The drugmaker attributed the anticipated drop in profit mainly to a lower gross profit margin and a rise in investment costs through online channels and offline advertising expenses.
Price (HKD): $1.01, Change: $-0.010, Percent Change: -0.98%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。